BCR and acute lymphoblastic leukemia: Our data suggest a similar relationship in Ph+ALL: ErbB inhibition with clinically achievable doses of lapatinib or canertinib sensitized ErbB2+Ph+ALL cells to treatment with BCR/ABL-directed TKI (Fig. 7A&B).